In dyW/mag mice carrying the chick mini-agrin transgene, daily CGP 3466B treatment significantly lowered blood CK levels compared with vehicle-treated dyW/mag mice. Treatment also reduced muscle fibre loss in this model without completely normalizing fibre numbers. In the EAE mouse model, treatment prevented GAPDH nitrosylation in spinal cord lysates, with maximal effect at 4 mg/kg. In ethanol-pretreated mice receiving APAP, treatment produced no statistically significant difference in serum ALT compared with EtOH/APAP alone. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Blood CK reduction in dyW/mag mice
Animal study · dyW/mag mice; C57BL/6J mice; N ≥ 6 ≤ 8 [1]
In dyW/mag mice carrying the chick mini-agrin transgene, daily omigapil treatment at 0.1 mg/kg significantly lowered blood CK levels compared with vehicle-treated dyW/mag mice.
Conditions shared by the study groups
- Route
- intraperitoneal injection; oral gavage
- Treatment course
- treatment started at the age of 15 days; For the first week of drug treatment; once daily; After weaning (3 weeks of age); Mice were analysed at the age of 12 weeks.
- Vehicle
- 0.5% ethanol
- CGP 3466B 0.1 mg/kg
- Model: dyW/mag mice; C57BL/6J mice; N ≥ 6 ≤ 8
Methods and source locations
Compound reported in the paper: CGP 3466B; Compound label in the paper: Omigapil
The paper names CGP 3466B without stating the salt or form; not verified as the maleate form supplied as A12385. No dose conversion or lot validation.
RESULTS > Pharmacological inhibition of apoptosis enhances amelioration by mini-agrin (S84, S86, S87); MATERIALS AND METHODS > Mice (S96, S100); MATERIALS AND METHODS > Treatment of dyW/mag mice with omigapil (S103, S104, S105, S106, S107); Figure 7 legend (S237, S238)
Blood CK levels expressed as percentage of control.: Blood CK levels expressed as percentage of control.; comparator: Age-matched animals treated with vehicle only — Figure 7 legend (S237, S238)
CGP 3466B 0.1 mg/kg · RESULTS > Pharmacological inhibition of apoptosis enhances amelioration by mini-agrin (S86); MATERIALS AND METHODS > Treatment of dyW/mag mice with omigapil (S103, S104, S105, S106); Figure 7 legend (S237, S238)
Prevention of GAPDH nitrosylation in EAE mice
Animal study · MOG35 − 55 EAE mouse model of MS; three mice per group [2]
In the EAE mouse model, daily intraperitoneal CGP3466b treatment prevented GAPDH nitrosylation in spinal cord lysates compared with vehicle, with maximal effect at 4 mg/kg.
Conditions shared by the study groups
- Route
- intraperitoneal (i.p.) injection
- Treatment course
- daily via intraperitoneal (i.p.) injection beginning on PID 0
- CGP 3466B 4 mg/kg
- Model: MOG35 − 55 EAE mouse model of MS; three mice per group
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: CGP 3466B
The paper names CGP 3466B without stating the salt or form; not verified as the maleate form supplied as A12385. No dose conversion or lot validation.
2. Results > 2.1. Neuroinflammation leads to GAPDH nitrosylation within the CNS in the MOG35 − 55 EAE mouse model of MS, which is prevented by CGP3466b treatment (S7, S8); Figure 1 legend (S48, S57, S59)
GAPDH nitrosylation was measured by biotin switch assay from spinal cord lysates at PID 15: GAPDH nitrosylation was measured by biotin switch assay from spinal cord lysates at PID 15; comparator: vehicle — 2. Results > 2.1. Neuroinflammation leads to GAPDH nitrosylation within the CNS in the MOG35 − 55 EAE mouse model of MS, which is prevented by CGP3466b treatment (S7, S8)
CGP 3466B 4 mg/kg · 2. Results > 2.1. Neuroinflammation leads to GAPDH nitrosylation within the CNS in the MOG35 − 55 EAE mouse model of MS, which is prevented by CGP3466b treatment (S7, S8); Figure 1 legend (S57)
Serum ALT response in ethanol and APAP exposed mice
Animal study · female C57BL/6J mice; ethanol pre-treated mice; n = 8 [3]
In ethanol-pretreated female mice receiving APAP, intraperitoneal TCH346 treatment at 0.2 mg/kg or 1.0 mg/kg produced no statistically significant difference in serum ALT compared with EtOH/APAP alone.
Conditions shared by the study groups
- Route
- intraperitoneal (IP) drug administration
- Treatment course
- fasted for 8 hours (h) before intraperitoneal (IP) drug administration, and sacrificed by CO2 inhalation after 4h
- Vehicle
- sterile PBS
- CGP 3466B 0.2 mg/kg; 1.0 mg/kg
- Model: female C57BL/6J mice; ethanol pre-treated mice; n = 8
Methods and source locations
Compound reported in the paper: CGP 3466B; Compound label in the paper: TCH-346
The paper names CGP 3466B without stating the salt or form; not verified as the maleate form supplied as A12385. No dose conversion or lot validation.
Materials and Methods > Liquid ethanol diet (S2, S3, S4); Materials and Methods > Drug treatments, blood and tissue processing (S6, S7, S8); Fig 3 legend (S70, S71)
Serum ALT levels: Serum ALT levels; comparator: EtOH/APAP alone — Materials and Methods > Drug treatments, blood and tissue processing (S6); Fig 3 legend (S70, S71)
CGP 3466B 0.2 mg/kg; 1.0 mg/kg · Materials and Methods > Drug treatments, blood and tissue processing (S6, S8); Fig 3 legend (S71)
Muscle fibre preservation in dyW/mag mice
Animal study · dyW/mag mice; C57BL/6J mice; N = 5 [1]
In dyW/mag mice carrying the chick mini-agrin transgene, daily omigapil treatment at 0.1 mg/kg reduced muscle fibre loss compared with vehicle-treated dyW/mag mice but did not completely normalize fibre numbers.
Conditions shared by the study groups
- Route
- intraperitoneal injection; oral gavage
- Treatment course
- treatment started at the age of 15 days; For the first week of drug treatment; once daily; After weaning (3 weeks of age); Mice were analysed at the age of 12 weeks.
- Vehicle
- 0.5% ethanol
- CGP 3466B 0.1 mg/kg
- Model: dyW/mag mice; C57BL/6J mice; N = 5
Methods and source locations
Compound reported in the paper: CGP 3466B; Compound label in the paper: Omigapil
The paper names CGP 3466B without stating the salt or form; not verified as the maleate form supplied as A12385. No dose conversion or lot validation.
RESULTS > Pharmacological inhibition of apoptosis enhances amelioration by mini-agrin (S84, S86, S87); MATERIALS AND METHODS > Mice (S96, S100); MATERIALS AND METHODS > Treatment of dyW/mag mice with omigapil (S103, S104, S105, S106, S107); Figure 7 legend (S237, S242, S243)
Total number of fibres per triceps cross-section.: Total number of fibres per triceps cross-section.; comparator: Age-matched animals treated with vehicle only — Figure 7 legend (S237, S242, S243)
CGP 3466B 0.1 mg/kg · RESULTS > Pharmacological inhibition of apoptosis enhances amelioration by mini-agrin (S86); MATERIALS AND METHODS > Treatment of dyW/mag mice with omigapil (S103, S104, S105, S106); Figure 7 legend (S237, S243)